Comprehensive guide to managing gastrointestinal adverse effects of GLP-1 receptor agonists
Timing: Early (first 4 weeks)
Severity: Usually mild-moderate
Timing: Early (first 4-8 weeks)
Severity: Usually indicates need for dose reduction
Timing: Variable (any time)
Severity: Usually self-limiting
Timing: Ongoing
Severity: Manageable
Timing: Variable
Severity: Usually mild
Timing: Ongoing
Severity: Manageable
2-3x higher risk
Higher nausea risk
Significantly increased
Dose-dependent increase
Naive patients at higher risk
More GI symptoms
Initiate at lowest dose (e.g., semaglutide 0.25mg) and stay for 4+ weeks before escalating. This allows tolerance to develop.
Taking the injection with a meal or shortly after can reduce nausea for many patients. Some do better on empty stomach - individualize.
Small, frequent meals (4-6/day) rather than large meals. Sip fluids throughout the day. Avoid lying down after eating.
Some patients tolerate evening injections better (sleep through initial nausea). Others prefer morning (can manage if nauseated during day).
Consider short-term ondansetron 4-8mg PRN during titration. May reduce nausea enough to improve adherence.
| Strategy | Description |
|---|---|
| Standard Titration | 4 weeks at each dose level - recommended for most patients |
| Extended Titration | 8-12 weeks at each dose for patients with significant GI symptoms |
| Split Dosing | Some patients tolerate 0.25mg twice weekly vs 0.5mg weekly |
| Back-loaded Dosing | Take larger portion of weekly dose later in week if symptoms occur after injection |
Discontinue GLP-1 therapy and seek medical evaluation if any of these occur: